Get the Stockscreener App
7.90
1.02%
0.08
Pre-market:
7.68
-0.22
-2.78%
Inmune Bio Inc stock is traded at $7.90, with a volume of 147.19K.
It is up +1.02% in the last 24 hours and up +5.05% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$7.82
Open:
$7.77
24h Volume:
147.19K
Relative Volume:
0.45
Market Cap:
$167.32M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-4.7305
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
+8.52%
1M Performance:
+5.05%
6M Performance:
+28.14%
1Y Performance:
-30.03%
1-Day Range:
$7.60
$7.96
1-Week Range:
$7.40
$8.67
52-Week Range:
$4.32
$12.72
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
7.90 | 167.32M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
A stock that deserves closer examination: INmune Bio Inc (INMB) - uspostnews.com
(INMB) Technical Data - news.stocktradersdaily.com
Inmune Bio Secures Favorable Patentability Opinion for CORDStrom™ - TipRanks
INmune Bio secures key patent opinion for CORDStrom platform By Investing.com - Investing.com South Africa
INmune Bio Receives Favorable Opinion from USPTO on CORDStrom Patent Application - marketscreener.com
INmune Bio Inc. Achieves Key Patent Milestone for CORDStrom™ Cell Therapy Platform - Nasdaq
INmune Bio secures key patent opinion for CORDStrom platform - Investing.com
Patent Win: INmune Bio's Revolutionary Cell Therapy Secures 20+ Years Protection - Stock Titan
INmune Bio (INMB) Advances with Positive Patent Opinion for CORD - GuruFocus
INmune Bio (INMB) Partners with CGT Catapult for Large-Scale Cel - GuruFocus
INmune Bio Partners with Cell and Gene Therapy Catapult - MSN
INmune Bio (INMB) Partners to Enhance Cell Therapy Production - GuruFocus
INmune Bio in pact with Cell and Gene Therapy Catapult (INMB) - Seeking Alpha
INmune Bio, CGT Catapult Partner To Scale CORDStrom Manufacturing For Commercial Launch - Nasdaq
INmune Bio Collaborating With Cell and Gene Therapy Catapult to Scale Manufacturing - MarketScreener
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness - The Manila Times
INmune Bio's Game-Changing Partnership Accelerates CORDStrom Production for 4,000 RDEB Patients - Stock Titan
Inmune Bio Presents Alzheimer’s Trial Data at Conference - TipRanks
INmune Bio, Inc. (NASDAQ:INMB) Receives $22.80 Average Price Target from Brokerages - Defense World
Trend Tracker for (INMB) - news.stocktradersdaily.com
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update - ADVFN
INmune Bio Presents MINDFuL Trial Data At AD/PD 2025 - Nasdaq
INmune Bio Presents Baseline Data From MINDFuL Phase II Trial In Early Alzheimer's Disease - Nasdaq
INmune Bio presents early Alzheimer’s trial data at AD/PD - Investing.com
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study - The Manila Times
INmune Bio presents early Alzheimer’s trial data at AD/PD By Investing.com - Investing.com UK
Raymond James maintains INmune Bio stock with $23 target By Investing.com - Investing.com Australia
Raymond James maintains INmune Bio stock with $23 target - Investing.com India
Raymond James Financial Inc. Takes Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio anticipates Alzheimer's trial results within 100 days while advancing therapeutic platforms - MSN
INmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Earnings Call Transcript - Insider Monkey
Scotiabank Remains a Buy on Inmune Bio (INMB) - The Globe and Mail
INmune Bio (INMB) Eyes Landmark Developments in 2024 Amid Rising Financial Commitments - GuruFocus
Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus - Investing.com Australia
INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategi - GuruFocus
INmune Bio Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus By Investing.com - Investing.com South Africa
INmune Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
INmune Bio Inc Reports Q4 EPS of -$0.53 and Revenue of $0.01 Mil - GuruFocus.com
INMUNE BIO Earnings Results: $INMB Reports Quarterly Earnings - Nasdaq
INmune Bio's Triple Threat: Alzheimer's Trial Fully Enrolled, FDA Designations Secured - Stock Titan
(INMB) On The My Stocks Page - news.stocktradersdaily.com
What to Expect from INmune Bio's Earnings - Benzinga
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 - The Manila Times
Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + - Seeking Alpha
INmune Bio (INMB) Projected to Post Quarterly Earnings on Thursday - Defense World
INmune Bio: CORDStrom Is A Game-Changer, As Investors Await Alzheimer's Results (INMB) - Seeking Alpha
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):